NCT04045145View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 (Crinecerfont) in Pediatric Participants With Congenital Adrenal Hyperplasia

PHASE2CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

December 12, 2019

Primary Completion Date

July 2, 2021

Study Completion Date

July 2, 2021

Conditions
CAH - Congenital Adrenal Hyperplasia
Interventions
DRUG

Crinecerfont

Crinecerfont administered orally for 14 consecutive days.

Trial Locations (6)

19104

Neurocrine Clinical Site, Philadelphia

48109

Neurocrine Clinical Site, Ann Arbor

55454

Neurocrine Clinical Site, Minneapolis

80045

Neurocrine Clinical Site, Aurora

92123

Neurocrine Clinical Site, San Diego

98105

Neurocrine Clinical Site, Seattle

Sponsors
All Listed Sponsors
lead

Neurocrine Biosciences

INDUSTRY